At the Cedars-Sinai Center Institute, Kobashigawa will serve as director of center transplantation, director of advanced cardiovascular disease and as the institute’s associate director for scientific affairs. During the last several years, it’s become obvious that the Cedars-Sinai Heart Institute can be on a trajectory to be among the world’s leading cardiovascular applications, having attracted many of the nation’s top heart doctors and researchers.D.D.D.D., Ph.D.D., Ph.D. Director, Post-Graduate Education in Center Failure and Transplantation. An additional member of the combined group, Babak Azarbal, M.D., procedures interventional cardiology with a concentrate on heart failure patients. Azarbal was chief resident during his inner medicine teaching at Cedars-Sinai. Related StoriesResearchers hyperlink organ transplant medication to rise in rare lymphomaBrain wellness: how can you decrease cognitive decline? An interview with Heather Snyder, Ph.D.Donor and patient age more essential in determining kidney transplant success Our team of doctors has always put patients initial, Kobashigawa said.International net sales improved 4 percent to $1.9 billion. Gross margin as a %age of net sales was 74.9 percent in the quarter compared to 72.3 percent in the same period a year ago. Advertising, selling and administrative expenditures increased 22 percent to $1.2 billion in the quarter. Advertising and product advertising spending elevated 5 percent to $285 million in the quarter. Research and development expenses remained smooth at $1.0 billion in the quarter. The effective taxes rate on revenue before income taxes was 22.8 percent in the quarter, in comparison to 40.4 percent in the fourth quarter last year. The Company reported net earnings attributable to Bristol-Myers Squibb of $852 million, or $0.50 per share, in the quarter in comparison to $483 million, or $0.28 per share, a year ago.